chrom,start_hg38,stop_hg38,start_hg19,stop_hg19,start_t2t,stop_t2t,notes_t2t,id,disease_id,repeatunit_pathogenic_geneorientation,repeatunit_path_plusstrand,disease,gene,repeatunit_ref,locus_structure,Inheritance,type,location_in_gene,normal,normal_min,normal_max,intermediate,intermediate_min,intermediate_max,pathogenic,pathogenic_min,pathogenic_max,ref_copies,repeatunitlen,age_onset,age_onset_min,age_onset_max,novel,Mechanism,Mechanism_detail,Mechanism_source,source,notes,width,repeatunit_path_norm,repeatunit,OMIM,Incidence,Prevalence,STRipy_gene,gnomAD_gene,GeneReviews
chrX,148500605,148500753,147582125,147582273,146765191,146765342,(GCC)51.3,FRAXE_AFF2,FRAXE,CGG,GCC,"Fragile X syndrome, FRAXE type",AFF2/FMR2,CGG,"""(GCC)*""",XR,5' UTR,5’ Region,4-39,4,39,,,,200-2000,200,2000,50.3,3,2-10,2,10,ref,"LOF, reduced gene expression",Loss of function via transcriptional silencing,(doi.org/10.1038/nrg1691) (doi.org/10.1007/s11604-022-01343-5),"Mirkin 2007, OMIM,  ""SourceId"": ""NBK535148""",,148,CCG,CGG,309548,,Unknown,AFF2,AFF2,NBK535148
chr2,100104799,100104824,100721261,100721286,100563686,100563738,(GCC)17.7,FRA2A_AFF3,FRA2A,CGG,CGG,Intellectual disability associated with fragile site FRA2A,AFF3,GCC,,AD,5' UTR,,3-20,3,20,,,,300,300,300,8.7,3,,,,ref,"Decreased gene expression, methylation","""silencing of the FMR2 gene as a consequence of a CCG expansion located upstream of this gene""",malacard,"https://doi.org/10.1038/s41580-021-00382-6, PMC3998887","Path threshold may actually be higher than 300, assay was not sensitive enough",25,CCG,,601464,,N/A,,,
chrX,67545317,67545419,66765159,66765261,65975148,65975250,(GCA)33.3,SBMA_AR,SBMA,CAG,GCA,"Spinal and bulbar muscular atrophy, Kennedy Disease",AR,CAG,"""(GCA)*""",XR,Coding,Exon 1,9–34,9,34,36-37,36,37,38–68,38,68,34,3,20-49,20,49,ref,Polyglutamine,Polyglutamine,(doi.org/10.1038/nrg.2017.115) (doi.org/10.1007/s11604-022-01343-5),"Hannan 2018, Mirkin 2007, GeneReviews,   ""SourceId"": ""NBK535148"", s40478-021-01201-x",,102,AGC,CAG,313200,,"1:300,000 males (SBMA); 1/40,000 (Kennedy Disease)",AR,AR,NBK1333
chrX,25013654,25013697,25031779,25031808,24597891,24597934,(GCC)14.7,EIEE1_ARX,EIEE1,GCG,NGC,Early-infantile epileptic encephalopathy,ARX,NGC," ""(NGC)*""",XR,Coding,Exon 2,10-16,10,16,,,,17-27,17,27,14.7,3,0,0,0,ref,Polyalanine,Polyalanine,(doi.org/10.1038/nature05977) (doi.org/10.1007/s11604-022-01343-5),"GeneReviews, OMIM,      ""SourceId"": ""NBK535148""",Exon 2 aa 110-115,43,CCG,GCG,308350; 300419; 300215,"1-2/100,000","~<1/35,000",ARX_1,ARX_1,NBK535148
chrX,25013530,25013565,25031647,25031682,24597767,24597799,(GGCCGCGGCGGCCGC)2.2,PRTS_ARX,PRTS,GCG,NGC,Partington syndrome,ARX,NGC,"""(NGC)*""",XR,Coding,Exon 2,12,12,12,,,,20,20,20,12,3,1-3,1,3,ref,Polyalanine,Polyalanine,(OMIM) (doi.org/10.1007/s11604-022-01343-5),"GeneReviews, OMIM, ""SourceId"": ""NBK535148""","Novel, Exon 2 aa 144-155",35,CCG,GCG,309510,,Unknown,ARX_2,ARX_2,NBK535148
chr12,6936717,6936775,7045880,7045938,6947904,6947941,(CAG)12.7,DRPLA_ATN1,DRPLA,CAG,CAG,Dentatorubral-Pallidoluysian Atrophy,ATN1,CAG,"""(CAG)*""",AD,Coding,Exon 5,3–35,3,35,,,,48-93,48,93,19,3,1-72,1,72,ref,Polyglutamine,Polyglutamine,(doi.org/10.1038/nrg.2017.115) (doi.org/10.1007/s11604-022-01343-5),"Hannan 2018, Mirkin 2007, GeneReviews, ""SourceId"": ""NBK535148"". s40478-021-01201-x",,58,AGC,CAG,125370,,"2-7/1,000,000",ATN1,ATN1,NBK1491
chr6,16327634,16327724,16327865,16327955,16200189,16200282,(TGC)31.1,SCA1_ATXN1,SCA1,CAG,TGC,Spinocerebellar Ataxia Type 1,ATXN1,CTG,"""(TGC)*""",AD,Coding,Exon 8,6–35,6,35,36-38,36,38,39–91,39,91,30.3,3,20-40 typical,13,60,ref,Polyglutamine,Polyglutamine,(doi.org/10.1038/nrg.2017.115) (doi.org/10.1007/s11604-022-01343-5),"Hannan 2018, Mirkin 2007, GeneReviews,     ""SourceId"": ""NBK1184"", s40478-021-01201-x",Interruptions: CAT,90,AGC,CTG,164400,,"1-2/100,000",ATXN1,ATXN1,NBK1184
chr22,45795355,45795424,46191235,46191304,46280060,46280129,(ATTCT)15.0,SCA10_ATXN10,SCA10,ATTCT,ATTCT,Spinocerebellar Ataxia Type 10,ATXN10,ATTCT,"""(ATTCT)*""",AD,Intronic,Intron 9/11,10–32,10,32,280-850,280,850,800-4500,800,4500,14,5,12-48,12,48,ref,Unknown,Transdominant mechanism theorized,(malacard),"Hannan 2018, Mirkin 2007, GeneReviews,     ""SourceId"": ""NBK535148"", s40478-021-01201-x",Interruptions: ATCCT,69,AATAG,ATTCT,603516,,Unknown,ATXN10,ATXN10,
chr12,111598950,111599019,112036754,112036823,111575873,111575940,(GCT)22.3,SCA2_ATXN2,SCA2,CAG,GCT,Spinocerebellar Ataxia Type 2,ATXN2,CTG,"""(GCT)*""",AD/AR,Coding,Exon 1,14–31,14,31,32-34,32,34,33–200,33,200,23.3,3,30-40 typical,25,50,ref,"Polyglutamine ","Polyglutamine ",(doi.org/10.1038/nrg.2017.115) (doi.org/10.1007/s11604-022-01343-5),"Hannan 2018, GeneReviews, ""SourceId"": ""NBK1275"", s40478-021-01201-x","29–32 repeats: increased ALS risk, Interruptions: CAA, CGG, CGC. Parkinson disease, late-onset, susceptibility.",69,AGC,CAG,183090,,"1-2/100,000 (population dependent)",ATXN2,ATXN2,NBK1275
chr14,92071012,92071053,92537356,92537397,86300520,86300603,(CTG)28.0,SCA3_ATXN3,SCA3_MJD,CTG,CTG,Spinocerebellar Ataxia Type 3/Machado-Joseph Disease,ATXN3,CTG,"""(GCT)*""",AD,Coding,Second last exon,12–44,12,44,45-59,45,59,60-87,60,87,14,3,10-50 typical,10,50,ref,"Polyglutamine ","Polyglutamine ",(doi.org/10.1038/nrg.2017.115) (doi.org/10.1007/s11604-022-01343-5),"Hannan 2018, Mirkin 2007, GeneReviews,  ""SourceId"": ""NBK535148"", s40478-021-01201-x","""14:92071009-92071042""",41,AGC,CTG,109150,,"1–5/100,000",ATXN3,ATXN3,NBK1196
chr3,63912685,63912716,63898361,63898392,63956303,63956334,(GCA)10.7,SCA7_ATXN7,SCA7,CAG,GCA,Spinocerebellar Ataxia Type 7,ATXN7,CAG,"""(GCA)*(GCC)+""",AD,Coding,"Exon 1, 2, or 3 (depending on isoform)",4–19,4,19,28-35,28,35,34–460,34,460,10.7,3,0-50,0,50,ref,"Polyglutamine ","Polyglutamine ",(doi.org/10.1038/nrg.2017.115) (doi.org/10.1007/s11604-022-01343-5),"Hannan 2018, Mirkin 2007, GeneReviews,   ""SourceId"": ""NBK535148"", s40478-021-01201-x",,31,AGC,CAG,164500,,"<1/300,000",ATXN7,ATXN7,NBK1256
chr13,70139383,70139429,70713515,70713561,69361244,69361271,(CTG)9.3,SCA8_ATXN8OS,SCA8,CTG,CTG,Spinocerebellar Ataxia Type 8,ATXN8OS/ATXN8,CTG,"""(CTA)*(CTG)*""",AD,3' UTR,Exon 5 or 3’ UTR depending on transcript,15–50,15,50,50-70,50,70,71-1300,71,1300,15.3,3,20-50 typical,1,73,ref,Polyglutamine/toxic gain-of-function,Polyglutamine/toxic gain-of-function,(OMIM) (doi.org/10.1007/s11604-022-01343-5),"Hannan 2018, Mirkin 2007, GeneReviews,  ""SourceId"": ""NBK535148"", s40478-021-01201-x","Two genes span the CTG/CAG repeat and are expressed in opposite directions: ATXN8, which encodes a nearly pure polyglutamine expansion protein in the CAG direction, and ATXN8OS (603680), which, when transcribed, produces a noncoding CUG expansion RNA (Moseley et al., 2006). Roda et al. suggested that the ATXN8 or ATXN8OS gene should not be evaluated in isolation as a candidate gene for spinocerebellar degenerative disease",46,AGC,CTG,608768,,"<1/100,000",ATXN8OS,ATXN8OS,NBK1268
chr16,66490397,66490466,66524300,66524369,72284667,72284761,(AATAA)19.4,SCA31_BEAN1,SCA31,TGGAA,TGGAA/TAGAA,Spinocerebellar Ataxia Type 31,BEAN1,AATAA,"""(TGGAA)*TAAAATAAAATAAAATAAAATAAAATAAAATAAAATAAAATAAAATAAAA""",AD,Intronic,Intron 4/4,0-10,0,10,,,,>110,110,760,14.4,5,20-72,20,72,novel,Epigenetic,"Role in heterochromatin or chromosomal structure theorized ",(OMIM),"OMIM, Sato 2009,    ""SourceId"": ""19878914"" (Pubmed), https://doi.org/10.1038/s41580-021-00382-6","Novel, STR-containing insertion, not present in reference genome: Reds disagree on normal/pathogenic sizes",69,AATGG,TGGAA,117210,,Unknown (more common in Japanese pop),BEAN1,BEAN1,NBK535148
chr9,27573484,27573546,27573482,27573544,27584063,27584155,(GCCCCG)15.8,FTDALS1_C9orf72,FTDALS1,GGGGCC,GGCCCC,Frontotemporal dementia (FTD) and/or amyotrophic lateral sclerosis (ALS),C9orf72,GCCCCG,"""(GGCCCC)*""",AD,Intronic,Intron 1 or 5' depending on transcript,3–25 (2-19 Reds),2,20,20-60,20,60,250-2000,250,2000,10.8,6,27-85,27,85,ref,RNA toxicity proposed,"""The HRE forms DNA and RNA G-quadruplexes with distinct structures and promotes RNA/DNA hybrids (R-loops). The structural polymorphism causes a repeat length-dependent accumulation of transcripts aborted in the HRE region.""",OMIM,"Hannan 2018, GeneReviews, OMIM,  ""SourceId"": ""NBK535148"", s40478-021-01201-x",,62,CCCCGG,GGGGCC,105500,,The expansion of a hexanucleotide repeat GGGGCC in C9orf72 is the most common known cause of ALS accounting for ~ 40% familial cases and ~ 7% sporadic cases in the European population,C9ORF72,C9ORF72,NBK268647
chr19,13207859,13207898,13318673,13318712,13333137,13333176,(CTG)13.3,SCA6_CACNA1A,SCA6,CAG,CTG,Spinocerebellar Ataxia Type 6,CACNA1A,CTG,"""(CTG)*""",AD,Coding,Last Exon: 47 or 48,4–18,4,18,19,19,19,20–33,20,33,13.3,3,19-73,19,73,ref,"Polyglutamine ","Polyglutamine ",(doi.org/10.1038/nrg.2017.115) (doi.org/10.1007/s11604-022-01343-5),"Hannan 2018, Mirkin 2007, GeneReviews,  ""SourceId"": ""NBK535148"", s40478-021-01201-x",,39,AGC,CAG,183086,,"<1/1,000,000",CACNA1A,CACNA1A,NBK1140
chr11,119206289,119206322,119076999,119077032,119226663,119226696,(CGG)11.3,JBS_CBL2,JBS,CCG,CCG,Jacobsen syndrome (FRAX11B fragile site),CBL2,CGG,"""(CGG)*""",AD,5' UTR,,<79,11,79,,,,>100,100,100,11.3,3,,0,0,ref,N/A,No information found,(OMIM),"https://doi.org/10.1038/s41580-021-00382-6, ""  ""SourceId"": ""7603564"" (PubMed)",,33,CCG,,147791,,"1/100,000 births",CBL,,
chr19,18786034,18786049,18896844,18896859,18921630,18921645,,EDM1-PSACH_COMP,"EDM1, PSACH",GTC,GTC,"Multiple epiphyseal dysplasia, Pseudoachondroplasia",COMP,GTC,,AD,Coding,,5,5,5,,,,4 or 6-7,6,7,5,3,13,13,13,ref,Protein LOF,"LOF, domain dependent",(https://pubmed.ncbi.nlm.nih.gov/29530484/),Pathogenic Short Tandem Repeats Gnomad v3.1.2,"Two diseases, same locus. Both expansions and contractions associated with disease",15,ACG,,132400; 177170,,"9-16/100,000 births",COMP,COMP,NBK1123; NBK1487
chr1,57367044,57367125,57832716,57832797,57245936,57245977,(AAAAT)8.6,SCA37_DAB1,SCA37,ATTTC,ATTTC,Spinocerebellar Ataxia Type 37,DAB1,AAAAT,"""(AAAAT)*(GAAAT)*(AAAAT)*""",AD,Intronic,Intron 1 (most isoforms),0-16,0,16,,,,31-75,31,75,16.6,5,18-64,18,64,novel,Protein toxic GOF,toxic gain-of-function mechanism,(OMIM),"Seixas et al 2017 AJHG,    ""SourceId"": ""NBK541729"", s40478-021-01201-x","Novel. Normal: [(ATTTT)7–400] Pathogenic: [(ATTTT)60–79(ATTTC)31–75(ATTTT)58–90], ATTTC within (ATTTT)7–400 repeat region",81,AAATG,ATTTC,615945,,"<1/1,000,000",DAB1,DAB1,NBK541729
chr12,50505002,50505022,50898785,50898805,50468096,50468116,,FRA12A_DIP2B,FRA12A,CGG,GGC,"Intellectual developmental disorder, FRA12A type",DIP2B,CGG,"""(GGC)*""",AD,5' UTR,,6-23,6,23,~139-206,139,206,~273-306,273,306,7,3,,1,1,ref,"Increased gene expression, methylation","Increased gene expression, methylation","(OMIM, https://www.medrxiv.org/content/10.1101/2022.09.12.22279739v3.full-text)","OMIM,  ""SourceId"": ""NBK535148"", path thresolds: https://www.medrxiv.org/content/10.1101/2022.09.12.22279739v3.full-text",,20,CCG,CGG,136630,,N/A,DIP2B,DIP2B,NBK535148
chrX,31284557,31284605,31302674,31302722,30882695,30882743,(TTC)22.7,DMD_DMD,DMD,TTC,TTC,Duchenne muscular dystrophy,DMD,TTC,,XR,Intronic,Intron 62,<33,16,33,,,,>59,59,59,16.7,3,dependent on repeat number (birth to adulthood),0,3,ref,Protein LOF,Functional defect in dystrophin/dystroglycan,(https://doi.org/10.1007/s10038-006-0056-7),"""Pathogenic Short Tandem Repeats",,48,AAG,,310200,,"1 in 3,500-5,000 live male births",DMD,DMD,NBK535148
chr19,45770204,45770266,46273462,46273524,48597739,48597756,,DM1_DMPK,DM1,CAG,CAG,Myotonic Dystrophy Type 1,DMPK,CAG,"""(CAG)*""",AD,3' UTR,Last exon,5–34,5,34,35-49,35,49,50-1000,50,1000,20.7,3,"0-30, mild up to 70",0,70,ref,RNA GOF,RNA gain-of-function - RNA gelation leading to misregulation of alternative splicing,(doi.org/10.1007/s11604-022-01343-5),"Hannan 2018, Mirkin 2007, GeneReviews,   ""SourceId"": ""NBK1165"", s40478-021-01201-x",Interruptions: CCG,62,AGC,CAG,160900,,"5-20/100,000",DMPK,DMPK,NBK1165
chr13,102161577,102161726,,,,,,SCA27B_FGF14,SCA27B,,AAG,Spinocerebellar ataxia 27B,FGF14,AAG,,AD,Intronic,Intron 1,,,,,,,,250,450,50.3,,,,,,,,,"https://www.omim.org/entry/620174, https://www.cell.com/ajhg/fulltext/S0002-9297(22)00506-7","250-300 pathogenic with incomplete penetrance, >300 complete penetrance",,,,620174,,,FGF14,,
chrX,147912037,147912111,146993555,146993629,146176665,146176769,(GGC)35.0,FXS_FMR1,FXS/FXTAS/POF1,CGG,CGG,"Fragile X syndrome (FXS), fragile X-associated tremor/ataxia syndrome (FXTAS), and fragile X-associated primary ovarian insufficiency FXPOI/POF1",FMR1,CGG,"""(CGG)*""",XD,5' UTR,Exon 2,5–44,5,44,45-200,45,200,200-2000,200,2000,20.6667,3,"FXS 2, FXTAS 60-65",2,65,ref,"LOF via decreased gene expression in FXS, GOF in FXTAS",Loss of function via transcriptional silencing in FXSRNA GOF in FXTAS,(doi.org/10.1038/nrg1691) (doi.org/10.1007/s11604-022-01343-5),"Hannan 2018, Mirkin 2007,     ""SourceId"": ""NBK1384""","FXTAS/POI 55–200, FXS >200, late onset",74,CCG,CGG,300624; 300623,,"16-25/100,000 males",FMR1,FMR1,NBK1384
chr3,138946020,138946062,138664862,138664904,141687014,141687051,(GCGGCTGCAGCCGCA)2.5,BPES_FOXL2,BPES,GCN,NGC,"Blepharophimosis, epicanthus inversus, and ptosis",FOXL2,NGC,"""(NGC)*""",AD,Coding,Exon 1,<14,14,14,,,,>15,15,15,14,3,"0, can have infertility in childbearing age",0,0,ref,Polyalanine,Polyalanine,(doi.org/10.1038/nature05977) (doi.org/10.1007/s11604-022-01343-5),"reds,  ""SourceId"": ""NBK535148""",,42,CNG,,110100,,"1 in 50,000 births globally",FOXL2,FOXL2,NBK535148
chr9,69037287,69037289,71652203,71652205,81210844,81210846,(AAG)9.7,FRDA_FXN,FRDA,AAG,GAA,Friedreich ataxia,FXN,GAA,"""(A)*(GAA)*",AR,Intronic,Intron 1,5–33,5,33,34-65,34,65,66 to 1700,66,1700,6,3,5-25,5,25,ref,"LOF, reduced gene expression",Loss of function via transcriptional silencing,(doi.org/10.1038/nrg1691) (doi.org/10.1007/s11604-022-01343-5),"Hannan 2018, Mirkin 2007, GeneReviews,   ""SourceId"": ""NBK535148""",Not annotated by TRF?,2,AAG,AAG,229300,,"1/50,000 (US), 1/40,000 (global)",FXN,FXN,NBK1281
chr19,14496041,14496074,"14,606,853",14606886,14622656,14622702,(CCG)15.7,OPDM2_GIPC1,OPDM2,CGG,CCG,Oculopharyngodistal myopathy,GIPC1,CCG,"""(CCG)*""",AD,5' UTR,Exon 1,6-29,6,29,,,,70-138,70,138,14.7,3,10-29,10,29,ref,RNA toxicity,RNA mediated toxicity hypothesized; unknown,"(OMIM),  (doi.org/10.1007/s11604-022-01343-5)","reds; ""Pathogenic Short Tandem Repeats Gnomad v3.1.2"", ""SourceId"": ""32413282"" (Pubmed)",,33,CCG,,618940,,Population dependent,GIPC1,GIPC1,NBK535148
chr2,190880873,190880920,191745599,191745646,191369983,191370024,(GCA)14.0,GDPAG_GLS,GDPAG,GCA,GCA,Glutaminase deficiency,GLS,GCA,"""(GCA)*""",AR,5' UTR,Exon 1,5-26,5,26,,,,90 - 1500,90,1500,16,3,Early childhood,0,1,ref,"Decreased gene expression, methylation",Change in histone modification decreases transcription,(OMIM),"van Kuilenburg 2019 NEJM, ""SourceId"": ""30970188"" (Pubmed)",Several compound het cases reported,47,AGC,GCA,618412,,"As of 2019, only 7 cases",GLS,GLS,NBK535148
chr7,27199678,27199732,27239297,27239351,27335815,27335849,(GCCGCGGCCGCCGCCG)1.9,HFG_HOXA13-III,HFG-III,GCN,NGC,Hand-foot-genital syndrome 3,HOXA13,NGC,"""(NGC)*""",AD,Coding,Exon 1,8-18,8,18,,,,24-32,24,32,18,3,0,0,0,ref,"Polyalanine ","Polyalanine ",(doi.org/10.1038/nature05977) (doi.org/10.1007/s11604-022-01343-5),"reds; ""Pathogenic Short Tandem Repeats Gnomad v3.1.2"", ""SourceId"": ""NBK1423""",There are 3 pathogenic polyalanine tracts in this gene,54,CNG,,140000,,Rare,HOXA13_3,HOXA13_3,NBK1423
chr7,27199825,27199861,27239444,27239480,27335914,27335954,(GCAGCCGCCGCCGCT)2.9,HFG_HOXA13-II,HFG-II,GCN,NGC,Hand-foot-genital syndrome 2,HOXA13,NGC,"""(NGC)*""",AD,Coding,Exon 1,12,12,12,,,,18,18,18,12,3,0,0,0,ref,"Polyalanine ","Polyalanine ",(doi.org/10.1038/nature05977) (doi.org/10.1007/s11604-022-01343-5),"reds; ""Pathogenic Short Tandem Repeats Gnomad v3.1.2"",     ""SourceId"": ""NBK1423""",There are 3 pathogenic polyalanine tracts in this gene,36,CNG,,140000,,Rare,HOXA13_2,HOXA13_2,NBK1423
chr7,27199924,27199966,27239543,27239585,27335920,27335951,(GCAGCCGCCGCCGCT)2.7,HFG_HOXA13-I,HFG-I,GCN,NGC,Hand-foot-genital syndrome 1,HOXA13,NGC,"""(NGC)*""",AD,Coding,Exon 1,14,14,14,,,,22,22,22,14,3,0,0,0,ref,"Polyalanine ","Polyalanine ",(doi.org/10.1038/nature05977) (doi.org/10.1007/s11604-022-01343-5),"reds; ""Pathogenic Short Tandem Repeats, Gnomad v3.1.2"" ""SourceId"": ""NBK1423""",There are 3 pathogenic polyalanine tracts in this gene,42,CNG,,140000,,Rare,HOXA13_1,HOXA13_1,NBK1423
chr2,176093058,176093103,176957786,17695783,176581179,176581220,(GGC)14.0,SD5_HOXD13,SD5,GCN,GCG,Syndactyly,HOXD13,GCG,"""(GCN)*""",AD,Coding,Exon 1,< 15,14,15,,,,>22,22,22,14,3,0,0,0,ref,Polyalanine,Polyalanine,(doi.org/10.1038/nature05977) (doi.org/10.1007/s11604-022-01343-5),"reds; ""Pathogenic Short Tandem Repeats Gnomad v3.1.2"", ""SourceId"": ""NBK535148""",,45,CNG,,186000,,Unknown,HOXD13,HOXD13,NBK535148
chr4,3074877,3074940,3076604,3076667,3073604,3073694,(CAG)30.3,HD_HTT,HD,CAG,CAG,Huntington disease,HTT,CAG,"""(CAG)*CAACAG(CCG)*""",AD,Coding,Exon 1,6–26,6,26,"27-35 unstable, 36-39 reduced penetrance",27,39,40–250 (>60 assocated with onset age <20),40,250,21.3,3,35-44,10,70,ref,"Polyglutamine ","Polyglutamine ",(doi.org/10.1038/nrg.2017.115) (doi.org/10.1007/s11604-022-01343-5),"Hannan 2018, Mirkin 2007, GeneReviews","CAG exp only pathogenic. Interruptions impact pathogenicity. Age 4 onset reported, not yet published",63,AGC,CAG,143100,,"1/10,000",HTT,HTT,NBK1305
chr16,87604283,87604329,87637889,87637935,93675724,93675776,(GCT)17.3,HDL2_JPH3,HDL2,CAG,CTG,Huntington disease-like 2,JPH3,GCT,"""(CTG)*""",AD,Coding,Exon 2,6–28,6,28,29-39,29,39,40–58,40,58,15.6667,3,12-66,12,66,ref,,"""unstable vertical transmission""",(doi.org/10.1007/s11604-022-01343-5),"Hannan 2018, Mirkin 2007, GeneReviews, ""SourceId"": ""NBK1529""",reflen + pos from HipSTR,46,AGC,CAG,606438,,"<1/1,000,000",JPH3,JPH3,NBK1529
chr8,"104,588,972","104,588,999","105,601,200","105,601,227","105,716,410","105,716,441",(CGC)10.7,OPDM1_LRP12,OPDM1,CGG,CGC,Oculopharyngodistal myopathy type 1,LRP12,CGC,"""(NCG)*""",AD,5' UTR,,13-45,13,45,,,,90,90,90,11.7,3,"Adult onset, variable (mean 22.1 in one study)",7,50,ref,RNA toxicity,RNA mediated toxicity hypothesized; unknown,"(OMIM),  (doi.org/10.1007/s11604-022-01343-5)","OMIM 164310, Ishiura et al [2019], Ehdn, ""SourceId"": ""NBK535148"", PMID 31332380",CGG/CGT,27,CCG,,164310,,Population dependent,LRP12,LRP12,NBK535148
chr5,10356339,10356411,10356451,10356523,10295521,10295593,(TTTTA)14.8,FAME3_MARCH6,FAME3,TTTCA,ATTTC,Familial adult myoclonic epilepsy type 3,MARCH6,TTTTA,,AD,Intronic,Intron 1,0,,,,,,"791-1,035 repeats",791,1035,14.8,5,10-40,10,40,novel,Unknown,Noted as unknown in literature,(OMIM),"Florian, R.T. Nat Comm. 2019",TTTTA + TTTCA,72,AAATG,TTTTA + TTTCA,613608,,"~<1/35,000",MARCHF6,MARCHF6,NBK535148
chr15,22786677,22786701,23086366,23086390,20458505,20458536,(GCG)10.7,ALS1_NIPA1,ALS1,GCG,GCG,Amyotrophic lateral sclerosis,NIPA1,GCG,"""(CGC)*""",AD,Coding,,6-10,6,10,,,,> 11,11,56,10.7,3,"Variable, 19-46 familial",19,46,ref,N/A,No information found,N/A  in GeneCard,"Pathogenic Short Tandem Repeats Gnomad v3.1.2, ""SourceId"": ""30342764"" (Pubmed), path range from gnomAD allele freqs",Proposed modifier for ALS,24,CCG,,105400,"1.5-4.7 per 100,000 person-years (All ALS, Europe/NA)","2.7-7.4/100,000 (All ALS, not just this locus)",NIPA1,NIPA1,
chr20,2652733,2652775,2633379,2633421,2683200,2683242,(GCCTGG)8.8,SCA36_NOP56,SCA36,GGCCTG,GGCCTG,Spinocerebellar ataxia type 36,NOP56,GGCCTG,"""(GGCCTG)*(CGCCTG)*""",AD,Intronic,Intron 1,3 to 14,3,14,15-649,15,649,650-2500,650,2500,7.2,6,~52 (mean),48,57,ref,Protein toxic GOF,toxic gain-of-function mechanism,(OMIM),"GeneReviews, OMIM, ""SourceId"": ""NBK231880""",,42,AGGCCC,GGCCTG,614153,,Unknown,NOP56,NOP56,
chr1,149390803,149390842,,,148519696,148519738,(GGC)14.3,NIID_NOTCH2NLC,NIID,GGC,GGC,"Neuronal intranuclear inclusion disease, Alzheimer disease and parkinsonism phenotype",NOTCH2NLC,CGG,,AD,5' UTR,5' Region,7–39,7,39,,,,66-517,66,517,13.3,3,16-76,16,76,ref,Unknown,May relate to methylation or RNA pathogenicity; Unknown,(OMIM)  (doi.org/10.1007/s11604-022-01343-5),"doi: 10.1038/s41588-019-0458-z https://doi.org/10.1016/j.ajhg.2019.05.013, s40478-021-01201-x","May be issues with parology between genes: C253572.1, NOTCH2, NOTCH2NL, NBPF14, NBPF19 ?? Motif variation in controls: (AGG)(CGG)n(AGG)0-3(CGG)0-2. Methylation involved",39,CCG,,603472,,Unknown,NOTCH2NLC,NOTCH2NLC,NBK535148
chr10,79826383,79826404,81586139,81586160,80695712,80695748,(GCG)12.7,OPML1_NUTM2B-AS1,OPML1,GGC,GGC,Oculopharyngeal myopathy with leukoencephalopathy 1,NUTM2B-AS1,GGC,,AD,lncRNA,Exon 1 (noncoding),3-16,3,16,,,,>700,700,700,7,3,,15,40,ref,RNA toxicity,"RNA mediated toxicity hypothesized, unknown",(OMIM)  (doi.org/10.1007/s11604-022-01343-5),"Pathogenic Short Tandem Repeats Gnomad v3.1.2, Ishiura 2019 doi: 10.1038/s41588-019-0458-z, https://doi.org/10.1038/s41580-021-00382-6","Not in TRF annotation, alt transcript in opposite direction: LOC642361",21,CCG,,618637,,Couldn't find,NUTM2B-AS1,NUTM2B-AS1,NBK535148
chr14,23321472,23321492,23790681,23790701,17522488,17522508,,OPMD_PABPN1,OPMD,GCG,GCG,Oculopharyngeal muscular dystrophy,PABPN1,CGG,"""(GCN)*""",AD/AR,Coding,Exon 1,10,10,10,,,,12-17,12,17,7,3,26-65,26,65,ref,"Polyalanine ","Polyalanine ",(doi.org/10.1038/nrg.2017.115) (doi.org/10.1007/s11604-022-01343-5),"Mirkin 2007, GeneReviews, ""SourceId"": ""NBK1126"", s40478-021-01201-x","AR for 11 repeats, AD >12 repeats. Most known patients have (GCG)+, but GCN or any polyalanine may be pathogenic",20,CCG,CGN,164300,,"1/100,000 Western countries",PABPN1,PABPN1,NBK1126
chr4,41745976,41746022,41747993,41748039,41719749,41719795,(GCC)15.7,CCHS_PHOX2B,CCHS,GCN,GCN,Congenital central hypoventilation syndrome,PHOX2B,GCC,"""(GCN)*""",AD,Coding,Exon 3,20,15,20,24,24,24,25-33,25,33,15.7,3,0-20,0,20,ref,Polyalanine,Polyalanine,(doi.org/10.1038/nature05977) (doi.org/10.1007/s11604-022-01343-5),"Mirkin 2007, GeneReviews, ""SourceId"": ""NBK1427"", s40478-021-01201-x","""ReferenceRegion"": ""4:41745971-41746032"",",46,CNG,GCN,209880,,1:148000-200000 births (Estimated),PHOX2B,PHOX2B,NBK1427
chr15,89333589,89333629,89876820,89876860,87088412,87088452,(GCT)13.7,CPEO_POLG,CPEO,CTG,GCT,"Progressive external ophthalmoplegia, Parkinson’s disease",POLG,GCT,"""(CTG)*TTG(CTG)*""",,,,"10-12, < 15",10,15,,,,> 10000,10000,10000,13.7,3,23-87,23,87,ref,N/A,No information found,N/A  in GeneCard,"""SourceDisplay"": ""Research only - contact CMMS KUH regarding findings"", PMC2905783",Unconfirmed association,40,AGC,,Disease association unclear,,,,,
chr5,146878728,146878759,146258291,146258322,147414734,147414765,(GCT)15.7,SCA12_PPP2R2B,SCA12,CAG,GCT,Spinocerebellar ataxia type 12,PPP2R2B,CAG,"""(GCT)*""",AD,Promoter,,4–32,4,32,,,,51–78,51,78,10.7,3,8-55,8,55,ref,Unknown,Noted as unknown in literature,"N/A in GeneCard,","Hannan 2018, Mirkin 2007, OMIM, ""SourceId"": ""NBK535148"", s40478-021-01201-x",(Roda et al. suggested that the ATXN8 or ATXN8OS gene should not be evaluated in isolation as a candidate gene for spinocerebellar degenerative disease),31,AGC,CAG,604326,,Unknown,PPP2R2B,PPP2R2B,NBK535148
chr9,130681606,130681639,133556993,133557026,142886569,142886595,(CGC)9.0,HSAN-VIII_PRDM12,HSAN VIII,GCC,GCC,Hereditary sensory and autonomic neuropathy type VIII,PRDM12,GCC,"""(GCC)*""",AR,Coding,Exon,<14,12,14,,,,>18,18,18,12,3,0,0,0,ref,"LOF, epigenetic","""mutations abrogated the histone-modifying potential of PRDM12, consistent with a loss of function""",OMIM,Pathogenic Short Tandem Repeats Gnomad v3.1.2,,33,CCG,,616488,,"<1/1,000,000",PRDM12,PRDM12,NBK535148
chr4,159342527,159342618,160263679,160263770,162693304,162693405,(TTTTA)20.4,FAME7_ RAPGEF2,FAME7,TTTCA,ATTTC,Familial adult myoclonic epilepsy type 7,RAPGEF2,TTTTA,"""(TTTTA)*(TTTCA)*(TTTTA)*""",AD,Intronic,Intron 14,0-1,0,1,,,,>=60,60,60,17.4,5,"~18, 23-37",18,37,novel,RNA toxicity,RNA toxicity hypothesized,(10.1038/s41588-018-0067-2),"Ishiura 2018, ""SourceId"": ""29507423"" (Pubmed), https://sci-hub.hkvisa.net/10.1111/ene.13848","Novel, (TTTTA)exp(TTTCA)exp(TTTTA)n, but only the TTTCA is specific to affected individuals, Alu-associated repeat, incomplete penetrance",91,AAATG,TTTCA,618075,,"~<1/35,000",RAPGEF2,RAPGEF2,NBK535148
chr4,39348425,39348483,39350045,39350103,39318078,39318136,(AAAAG)11.8,CANVAS_RFC1,CANVAS,AAGGG/ACAGG,AAGGG,"Cerebellar ataxia, neuropathy, and vestibular areflexia syndrome",RFC1,AAAAG,"""(AARRG)*""",AR,Intronic,Intron 2,0-11,0,11,,,,>400,400,2000,11.8,5,33-71,33,71,novel,N/A,No information found,N/A  in GeneCard,"OMIM, Cortese 2019, ""SourceId"": ""30926972"" (Pubmed), https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-021-01201-x/tables/1, s40478-021-01201-x","Novel, ref is AAAAG(11), path: (AAGGG)400–2000 or (ACAGG)exp",58,AAGGG,AAGGG,614575,,"<1/1,000,000",RFC1,RFC1,NBK564656
chr12,123533720,123533755,124018267,124018302,123532574,123532608,(GGC)11.7,OPDM4_RILPL1,OPDM4,CGG,GGC,Oculopharyngodistal myopathy type 4,RILPL1,CGG,,AD,5' UTR,,9-16,9,16,,,,139 to 197,139,197,11.7,3,,14,27,ref,Protein toxic GOF,"toxic gain-of-function mechanism ",(Malacard),Yu 2022 AJHG,toxic poly-glycine protein and/or toxic RNA gain-of-function effects,35,CCG,,,,Population dependent,RILPL1,,
chr6,45422750,45422792,45390487,45390529,45257567,45257611,(GGC)15.0,CCD_RUNX2,CCD,GCN,GCN,Cleidocranial dysplasia,RUNX2,GCN,"""(GCN)*""",AD,Coding,Exon 3,<17,4,17,,,,>27,27,27,15,3,0,0,0,ref,Polyalanine,Polyalanine,(doi.org/10.1038/nature05977) (doi.org/10.1007/s11604-022-01343-5),"reds; ""Pathogenic Short Tandem Repeats Gnomad v3.1.2"",  ""SourceId"": ""NBK535148""",,42,CNG,,119600,,"1/1,000,000 births (likely underdiagnosed)",RUNX2,RUNX2,NBK1513
chr8,118366813,118366918,119379052,119379157,119495248,119495353,(AAATA)21.6,FAME1_SAMD12,FAME1,TTTCA/TTTGA,ATTTC,Familial adult myoclonic epilepsy type 1,SAMD12,AAATA,"""(TAAAA)*(TGAAA)*(TAAAA)*""",AD,Intronic,Intron 4/4,0,0,0,,,,105–3680,105,3680,21.6,5,18-50,18,50,novel,RNA toxicity proposed,RNA molecules,(OMIM),Ishiura 2018. https://movementdisorders.onlinelibrary.wiley.com/doi/full/10.1002/mds.27832 reported TTTGA expansions in affected individuals: (TTTTA)114-123(TTTGA)108-116,"Novel, pathogenic alleles include expansions of TTTTAn + TTTCAn, but only the TTTCA is specific to affected individuals, check reference and pathogenic sites with Stranger. TTTCA within TTTTA repeat region",105,AAATG,TTTCA,601068,,"~<1/35,000",SAMD12,SAMD12,NBK535148
chrX,140504316,140504361,139586481,139586526,138816205,138816239,(GCGGCAGCGGCGGCGG)1.9,XLMR_SOX3,XLMR,GCN,NGC,"X-linked panhypopituitarism ;  X-linked mental retardation with isolated growth hormone               ",SOX3,NGC,"""(NGC)*""",XR,Coding,Exon 1,< 15,15,15,,,,> 22,22,26,15,3,Infancy - childhood,0,9,ref,Polyalanine,Polyalanine,(doi.org/10.1007/s11604-022-01343-5),"reds; ""Pathogenic Short Tandem Repeats Gnomad v3.1.2"",   ""SourceId"": ""NBK535148""",,45,CNG,,300123,,,SOX3,SOX3,NBK535148
chr2,96197067,96197121,96862805,96862859,96703675,96703729,(AAAAT)11.6,FAME2_STARD7,FAME2,GAAAT,ATTTC,Familial adult myoclonic epilepsy 2,STARD7,AAAAT,,AD,Intronic,,0,0,0,,,,>274,274,274,11.6,5,mean 25,5,60,novel,RNA toxicity,"RNA toxicity ",(10.1038/s41467-019-12671-y),Pathogenic Short Tandem Repeats Gnomad v3.1.2,,54,AAATG,,607876,,"~<1/35,000",STARD7,STARD7,NBK535148
chr6,170561907,170562017,170870995,170871105,171935459,171935569,(GCA)37.0,SCA17_TBP,SCA17,CAG/CAA,GCA,Spinocerebellar ataxia type 17,TBP,CAG,"""(GCA)*""",AD,Coding,Exon 3,25–40,25,40,41–48,41,48,49 to 66,49,66,37,3,Most >30,3,55,ref,"Polyglutamine ","Polyglutamine ",(doi.org/10.1038/nrg.2017.115) (doi.org/10.1007/s11604-022-01343-5),"Hannan 2018, Mirkin 2007, GeneReviews,  ""SourceId"": ""NBK1438""","Parkinson disease,late-onset",110,AGC,CAG/CAA,607136,,"0.47:1,000,000 (Japanese)",TBP,TBP,NBK1438
chr22,19766762,19766807,19754285,19754330,20143615,20143660,,OTF_TBX1,OTF,GCN,GCN,Tetralogy of Fallot,TBX1,GCN,"""(GCN)*""",AD,Coding,,<15,15,15,,,,>25,25,25,15,3,0,0,0,ref,Polyalanine,Polyalanine,(OMIM),"Pathogenic Short Tandem Repeats Gnomad v3.1.2, ""SourceId"": ""NBK535148""",,45,CNG,,187500,,Unknown for specific gene,TBX1,TBX1,NBK535148
chr18,55586155,55586227,53253386,53253458,55789234,55789288,(AGC)18.3,FECD3_TCF4,FECD3,CAG,CAG,Fuchs endothelial corneal dystrophy 3,TCF4,CAG,"""(CAG)*""",AD,Intronic,Intron 1,10 - 40,10,40,,,,>50,50,150,25.3,3,~40,32,70,ref,RNA toxicity proposed,"""sequestration of MBNL1 in RNA foci, similar to the mechanism underlying myotonic dystrophy-1 """,(10.1074/jbc.M114.621607),"reds; ""Pathogenic Short Tandem Repeats Gnomad v3.1.2"", ""SourceId"": ""NBK535148""",,72,AGC,,613267,,~4/100 (over 40),TCF4,TCF4,NBK535148
chr16,24613439,24613532,24624760,24624853,24890367,24890430,(ATTTT)12.8,FAME6_ TNRC6A,FAME6,TTTCA,ATTTC,Familial adult myoclonic epilepsy type 6,TNRC6A,ATTTT," ""(TTTTA)*(TTTCA)*(TTTTA)*""",AD,Intronic,,0,0,0,,,,">1100, >=10, 29",1100,1100,18.8,3,20s-70s,20,70,novel,RNA toxicity,RNA toxicity hypothesized,(10.1038/s41588-018-0067-2),"Ishiura 2018; gnomad v3.1.2, ""SourceId"": ""29507423"" (Pubmed), https://doi.org/10.1038/s41597-020-00633-9, https://stripy.org/database/TNRC6A","Novel, reported pathogenic alleles: (TTTTA)22 (TTTCA)exp (TTTTA)exp, but only the TTTCA is specific to affected individuals, Alu-associated repeat. Non-pathogenic reference TTTTA repeat was expanded in nine healthy subjects 40-120 repeats and in two individuals potentially even longer (Ishiura et al., 2018).",93,AAATG,TTTCA,618074,,"~<1/35,000",TNRC6A,TNRC6A,NBK535148
chr16,17470921,17470922,17564778,17564779,17477910,17478013,(GCC)34.7,DBQD2_XYLT1,"DBQD2, BSS",CCG,GCC,Baratela-Scott Syndrome/Desbuquois dysplasia 2,XYLT1,CCG,"""(GGC)*""",AR,Promoter,Intron 1,<20,0,20,,,,>72,72,110,0,3,0,0,0,ref,Methylation,Methylation,(doi.org/10.1016/j.ajhg.2018.11.005),"LaCroix 2019; reds, gnomad v3.1.2, ""SourceId"": ""30554721""",Repeat is within a sequencing missing from hg38,1,CCG,CCG,615777,,"<1 / 1,000,000 births",XYLT1,XYLT1,NBK535148
chr3,183712188,183712222,183429976,183430010,186521657,186521706,(ATTTT)10.0,FAME4_YEATS2,FAME4,TTTCA,ATTTC,Familial adult myoclonic epilepsy 4,YEATS2,TTTTA,,AD,Intronic,,0,0,0,,,,>1000,1000,1000,10,5,19.5 years (range 10-33) for tremor and 25 years (range 19-33) for seizures,10,33,novel,RNA toxicity,RNA toxicity hypothesized,(10.1093/brain/awz267),Pathogenic Short Tandem Repeats Gnomad v3.1.2,,34,AAATG,,615127,,"~<1/35,000",YEATS2,YEATS2,NBK535148
chr13,99985448,99985493,100637702,100637747,99196359,99196404,(GCG)15.3,HPE5_ZIC2,HPE5,GCN,GCN,Holoprosencephaly-5,ZIC2,GCN,"""(GCN)*""",AD,Coding,Exon 3,< 15,15,15,,,,>25,25,25,15.3,3,0,0,0,ref,"Polyalanine ","Polyalanine ",(doi.org/10.1038/nature05977) (doi.org/10.1007/s11604-022-01343-5),"reds; ""Pathogenic Short Tandem Repeats Gnomad v3.1.2"", ""SourceId"": ""NBK535148""",,45,CNG,,609637,,Unknown ZIC2 specific,ZIC2,ZIC2,NBK535148
chrX,137566826,137566856,136648985,136649015,135876774,135876800,(CGC)9.0,VACTERLX_ZIC3,VACTERLX,GCN,GCN,X-linked VACTERL syndrome,ZIC3,GCN,"""(GCN)*""",XR,Coding,,<10,9,10,11,11,11,>12,12,12,9,3,0,0,0,ref,Polyalanine,Polyalanine,(doi.org/10.1038/nature05977),"Pathogenic Short Tandem Repeats Gnomad v3.1.2, ""SourceId"": ""NBK535148""",,30,CNG,,314390,,Unknown,ZIC3,ZIC3,NBK535148
chr7,55887601,55887639,55955294,55955332,56047901,56047939,(GCG)15.0,FRA7A_ZNF713,FRA7A,CGG,CGG,Autism spectrum disorder associated with fragile site FRA7A,ZNF713,GCG,,AD,Intronic,,5-22,5,22,85,85,85,450,450,450,13,3,,,,ref,Methylation,Methylation,(OMIM),"OMIM, https://pubmed.ncbi.nlm.nih.gov/25196122/",,38,CCG,,#616181,,N/A,,,
chr3,129172577,129172659,128891420,128891502,131917483,131917557,(CAGG)18.8,DM2_CNBP1,DM2,CCTG,CAGG,Myotonic Dystrophy Type 2,ZNF9 / CNBP1,CAGG,"""(CAGG)*(CAGA)*(CA)*""",AD,Intronic,,11–26,11,26,27-74,27,74,"75-11,000",75,11000,20.8,4,~30-40,30,40,ref,Aberrant splicing,Aberrant splicing,(doi.org/10.1093/hmg/ddr568),"Hannan 2018, Mirkin 2007, GeneReviews NBK1466, https://doi.org/10.1038/s41580-021-00382-6",(TG)n(TCTG)n(CCTG)n. CCTG expansion causes DM2 but the other repeat units are also variable.,82,AGGC,CCTG,602668,,"2.29/100,000",CNBP,CNBP,NBK1466